JHL Biotech, Inc. (GTSM:6540) is looking to raise $250 million by re-listing on another stock exchange after taking its shares off Taiwan’s bourse. The company needs to fund costly clinical trials for the cancer drugs it is developing. “We want to raise $250 million, which demands a market valuation of $1 billion and we are not going to get that on the Taipei Exchange,” said Chief Executive Racho Jordanov.